Table 2.

Postdiagnosis vitamin supplement use in association with total mortality and breast cancer recurrence, SBCSS (N = 4,877)

Total mortalityBreast cancer recurrence
Vitamin useCohortNo. of eventsHRa (95% CI)PNo. of eventsHRa (95% CI)P
Never postdiagnosis3,1012971.00 (referent)3571.00 (referent)
Any type
Postdiagnosis use1,7761470.88 (0.72–1.08)0.231750.84 (0.70–1.01)0.06
Duration of use
 ≤3 mo547561.09 (0.81–1.45)0.57600.90 (0.69–1.19)0.48
 >3 mo1,229910.79 (0.62–1.00)0.051150.81 (0.65–1.00)0.05
Multivitamins
Postdiagnosis use535360.82 (0.57–1.17)0.27410.74 (0.53–1.03)0.08
Duration of use
 ≤3 mo225181.01 (0.63–1.64)0.96160.70 (0.42–1.17)0.17
 >3 mo310180.69 (0.42–1.11)0.12250.77 (0.51–1.16)0.21
Vitamin Eb
Postdiagnosis use297220.71 (0.46–1.11)0.13250.65 (0.43–0.97)0.04
Duration of use
 ≤3 mo128130.97 (0.55–1.70)0.90130.74 (0.42–1.29)0.29
 >3 mo16990.52 (0.27–1.01)0.05120.57 (0.32–1.01)0.05
Vitamin Cb
Postdiagnosis use746610.81 (0.61–1.07)0.13780.81 (0.63–1.03)0.09
Duration of use
 ≤3 mo339381.08 (0.77–1.52)0.66461.00 (0.74–1.37)0.98
 >3 mo407230.56 (0.37–0.87)0.009320.62 (0.43–0.90)0.01
Any antioxidantc
Postdiagnosis use1,3801070.82 (0.65–1.02)0.081290.78 (0.63–0.95)0.02
Duration of use
 ≤3 mo537601.13 (0.85–1.50)0.40630.92 (0.70–1.21)0.56
 >3 mo843470.60 (0.44–0.82)0.001660.67 (0.51–0.88)0.004
  • aHRs are adjusted for ER/PR status, TNM stage, chemotherapy, radiotherapy, tamoxifen use, education, income, BMI, regular tea consumption, regular exercise participation (MET-hours per week), daily cruciferous vegetable intake, daily soy protein intake, and other vitamin variables in the table. Adjusted HRs and their corresponding 95% CIs were derived from Cox proportional hazards regression models, using age as the time scale.

  • bExcludes women who took a multivitamin (n = 535).

  • cIncludes women who used vitamin C, vitamin E, and/or multivitamins.